An aspect of the ethics of the medication-free research debate is the question of long-lasting damage from short-term psychosis. Data from medication-free research refute the hypothesis that short-term increase in psychosis during research causes long-term deterioration. More compelling are the preneuroleptic biased cohort studies, which suggest that years of untreated psychosis increase the incidence of poor outcome cases. Comprehensive treatment involves many therapeutic elements. In regard to pharmacotherapy, it is generally the case that the more aggressive drug treatment is associated with less psychosis, but more negative symptoms, poorer medication compliance, more depression, and more adverse drug effects. These complexities must be considered in evaluating ethical and safety issues. Standards should be high, and the evidence suggests that treatment in the context of research can (and usually does) meet these standards.
National Institute of Mental Health-sponsored research at the University of California at Los Angeles included a medication withdrawal protocol in first-episode patients with a schizophrenia diagnosis. Extensive media attention followed allegations that this research was unethical and had harmed the patients. In 1994 the National Institutes of Health, Office for Protection From Research Risks investigated these allegations and found the research ethical, the clinical care ethical, and no evidence of harm to study participants. They did consider the consent form inadequate in description of risk and required revision. Nevertheless, a national debate on the ethics and clinical care propriety of off-medication research (including placebo-controlled clinical trials) has been ignited.
In discussion of this issue, opinions expressed by ethicists and others reflect a remarkable ignorance of schizophrenia and of the treatment of persons afflicted with this illness. These authors inform their readers that medication withdrawal scars the brain, causes long-term morbidity and suicide, and should be regarded ethically as equivalent to withholding insulin from diabetic patients or immunosuppressant drugs during organ transplant surgery (Katz 1993; Willwerth 1993; Hilts 1994a, 19946) .
Wyatt has postulated that psychosis is neurotoxic and that delay in treatment causes long-lasting adverse consequences (Wyatt 1991 (Wyatt , 1995a . These hypotheses (he regards the former as speculative and the latter as suggested by data but not yet established) are cited by others as documentation of the harm alleged to result from medication-free research. Misrepresentation of Wyatt's views distorts consideration of the safety and ethics of medication-free research. Wyatt and I have discussed these issues and have little disagreement on fact, narrow divergence in opinion on the central issues, but more significant differences about data interpretation and emphasis. This exchange provides an opportunity to clarify our views.
Wyatt and I agree on the following:
1. Early detection of psychosis and rapid initiation of treatment are desirable.
2. Relapse prevention is vitally important. 3. Some cases with a single episode of psychosis will prove not to have a recurrent illness, challenging the wisdom of years of continuous neuroleptic drugs for prophylactic purposes in all single-episode cases.
4. Lengthy medication-free research with subjects who have a treatment-responsive psychosis is undesirable.
5. The hypothesis that the distress of psychosis may cause neurotoxicity is plausible, but speculative.
I stress the importance of early detection and rapid initiation of treatment because it is clinically prudent to reduce symptoms and prevent relapse. However, antipsychotic drug therapy is only one component of treatment.
In Falloon's successful early detection/prevention study, psychosocial treatment was initiated in all cases, but neuroleptic drugs were used in only about one-third of them (Falloon 1992) . This point underscores the inadequacy of defining treatment exclusively in pharmacological terms when considering the ethics of "withholding treatment" for research.
Despite therapeutic effects in most patients, it has been difficult to document that antipsychotic drugs have remarkably changed the long-term outcome of schizophrenia. The studies Wyatt cites as epidemiological and mirror-image evidence of long-term neuroleptic benefits suggest a small effect (McWalter et al. 1961; 0degard 1964; Peterson and Olson 1964; Astrup and Noreik 1966; Pritchard 1967a, 19676; Murakami 1971; Shimazono 1973; Bockoven and Solomon 1975; Huber et al. 1979 Huber et al. , 1980 Watt et al. 1983) . Even if this effect is real, Wyatt and I agree that neuroleptic treatment is not established as the cause.
Data on decreasing incidence and severity of schizophrenia are decisive only if population-based and comparable assessment data are collected. The data reviewed, however, are from treated (rather than representative) cohorts, and outcomes are estimated with data that are different in content and meaning in the two time periods being compared. Effective treatment, reduction in stigma, and more extensive and community-based mental health services would increase the number of better prognostic patients in treated cohorts. Correction of the bias inherent in institution-based sampling would give the appearance of a less severe illness in subsequent cohorts. A shift over time in hospital policy regarding discharge introduces a systematic bias if time in hospital is considered a measure of the severity of illness. Estimating change in schizophrenia incidence from the diagnosis of treated samples is flawed given the shifts in diagnostic practice and in accessibility of services over time. It would not, for example, be valid to credit lithium with preventing schizophrenia and causing manic-depressive disorder because the diagnosis of the former decreased and if the latter increased in the United States following the introduction of effective lithium therapy. Hospital stays decreased because of deinstitutionalization policy, but homeless persons with schizophrenia can attest to the fact that this change does not reflect eradication of the morbid process.
The proposition that psychosis (rather than the natural course of illness) causes increased morbidity over time faces a severe challenge from the long-term followup studies. Progression of the illness and development of the residual, deficit, or defect state occur early, often preceding psychosis. Angst (1988) , reviewing the European studies, and McGlashan (1988) , reviewing the North American data, both conclude that the illness does not typically progress after the initial approximately 5 years. Angst (1988) , noting that Bleuler (1978) and Huber et al. (1980) both confirmed that the defect state did not progress after 5 years, reported a prospective study showing no further decline in defect state after four episodes (Angst et al. 1981) . These findings complicate the "psychosis is neurotoxic" theory by requiring an explanation as to why this hypothesized effect is lost as cumulative time psychotic increases.
Wyatt cites reports by Crow et al. (1986) , Johnstone et al. (1990) , and Loebel et al. (1992) to indicate that delay in initiating antipsychotic drug treatment at first psychosis is associated with a worse long-term course. A large body of work (Stephens and Astrup 1963; Vaillant 1964a, 19646; Stephens et al. 1966; Stephens 1978; McGlashan 1988) establishes insidious onset as a robust poor prognostic factor; greater delay in initiating treatment is expected in such patients. Insidious onset and delayed treatment are not mutually exclusive as poor prognosis factors, but the former confounds the interpretation of the latter. Loebel et al. (1992) suggest a role for delayed treatment in explaining the level of remission and the time to remission of first psychotic episode (not long-term course) independent of a measure of abruptness of onset. Mode of onset of nonpsychotic symptoms is not predictive in their data, but this does not undermine the substantial evidence for insidious onset as a poor prognostic factor. Loebel and colleagues are quite circumspect in their interpretation and note that male sex, poor premorbid adjustment, duration of psychotic symptoms, and age at onset were all associated with either the level or the rate of remission. Being male correlated with duration of illness before treatment. They consider several explanations for this finding, but the most parsimonious interpretation is that the later an intervention takes place, the more sluggish the response for that episode. This is characteristic of most diseases.
The myriad confounds of this sort in the studies cited by Wyatt undermines their relevance to understanding drug treatment effects on long-term course. The assertion that these data are relevant to a consideration of medication-free research is a further stretch. I contend that the substantial evidence from random assignment prospective studies is far less biased and more decisive (Mosher and Menn 1978; Matthews et al. 1979; Carpenter and Heinrichs 1983; Curson et al. 1986; Carpenter et al. 1987 Carpenter et al. , 1990 Kreisman et al. 1988; Jolley et al. 1989 Jolley et al. , 1990 Herz etal. 1991; Schooler 1991; Pietzcker et al. 1993; Schooler et al. 1993) . These studies, with followup periods of 9 months to 7 years, contain key elements of current research designs missing in the May et al. (1981) study (see below). The experimental groups differed significantly in psychotic symptom exacerbation from contemporaneous and randomly assigned control patients. Therefore, testing the hypothesis of prolonged adverse effects as a consequence of inadequate pharmacotherapy is credible. Results generally indicate that the course following psychotic exacerbation reflects advantages for negative symptoms and adverse drug effects in the experimental groups. There was extensive similarity in other symptoms (including psychosis) and social functioning at outcome between groups. These studies refute the hypothesis that today's medication-free research causes adverse consequences in illness course following symptom exacerbation.
These data do not, however, test the hypothesis that months or years of untreated psychosis adversely alter the morbid process. The data that Wyatt discusses are particularly interesting regarding the incidence of a catastrophic form of schizophrenia in the postneuroleptic era. Bleuler (1978) observed a decrease in the proportion of acuteonset cases with a catastrophic course (from more than 10% in the preneuroleptic era to about 5%). Huber et al. (1980) found fewer cases progressing to a defect state, and Waddington et al. (1995) report that patients who were psychotic for years before receiving neuroleptic drugs were more likely to develop mutism. Although not proven as a drug effect, it may be that the most robust effect of antipsychotic drug treatment over the long term is to reduce the incidence of this severe (but uncommon) course pattern. If so, this is a profound accomplishment, but it does not imply that weeks in medication-free research increases risk for a catastrophic course.
The clinical reasoning for effective administration of antipsychotic drug therapy is compelling, and speculation that brief periods of medication-free research cause brain damage and long-lasting morbidity are not required to support the view that early intervention and relapse prevention are basic to schizophrenia therapeutics. However, all treatment approaches in schizophrenia are associated with substantial risk. The single-episode patient creates a dilemma because long-term drug continuation will expose a minority of patients to more risk than benefit, while medication discontinuation will expose the majority of patients to an increased risk of exacerbation. It seems advisable, therefore, to establish stability (perhaps a year) on medication followed by gradual dose reduction until the patient is medication free. Close monitoring can detect early warning signs of relapse and trigger intervention, which is usually effective. A similar consideration may be applicable in chronic cases as psychosis becomes less intense and neuroleptic risks increase with age.
Psychosis may be neurotoxic. The plausibility of this hypothesis is based on stress experiments in animals (Virgin et al. 1991; McEwen et al. 1992; Sapolsky 1993 Sapolsky , 1994 Moghaddam et al. 1994; Coplan et al. 1996; Ladd et al. 1996) and what may be stress-or distress-mediated effects in torture victims and post-traumatic stress disorders (Jensen et al. 1982; Kellner et al. 1983; Bremner et al. 1995) . If such a distress-mediated effect is associated with schizophrenia, closely monitored, carefully conducted, brief periods of medication-free research are not the problem. Patients typically have years of morbidity with associated distress preceding the first diagnosis and treatment (Asarnow 1988; Loebel et al. 1992; Hafner and Maurer 1995; Hafner and Nowotny 1995) . After treatment has been initiated, medication noncompliance is common and is a major source of psychotic exacerbation (Weiden and Olfson 1995) . Furthermore, patients experience psychosis while receiving antipsychotic drugs, and these medications also induce distressing subjective experience.
If there is a neurotoxic consequence of schizophrenia, the long periods of distress during the developmental years preceding first treatment and the extensive experience of psychosis for many patients while receiving medication or during noncompliant periods seem far more dangerous than, say, a 6-week medication-free protocol period with provisions for early intervention. It is surprising that speculation regarding psychosisinduced neurotoxicity enters the debate on research ethics. First, consider that neuroleptic drugs do not have an established role in preventing neurotoxicity. Second, time in medication-free research dwarfs in comparison with the time of dysphoric experience in the life of a person with schizophrenia. Third, evidence noted above suggests that research involvement does not adversely affect the course of the illness, even if a period of increased psychosis is involved. Fourth, no scientific evidence supports the neurotoxicity of psychosis hypothesis. Fifth, neuroleptic drugs are known to cause brain changes and dysphoric symptoms (Lerner et al. 1977; Van Putten and May 1978a; Benes et al. 1983; Van Putten and Marder 1987; Meshul and Casey 1989; Gariano et al. 1990; Jeste et al. 1992; Wisniewski et al. 1994; King et al. 1995; Roberts et al. 1995) and prolong the experience of depression (Shanfield et al. 1970; McGlashan and Carpenter 1976a, 1976ft; Van Putten and May 1978ft; Mandel et al. 1982; Galdi 1983; Bartels and Drake 1988; Leff et al. 1988) .
Ethicists and other writers may present a brain damage argument to uninformed lay readers, intending to excite a negative response to medication-free research, rather than informing readers about the treatment of schizophrenia and the scientific status of benefits and risks associated with that medication-free research. The presentation of concerns would be more balanced if these writ-ers informed readers that course of illness variables such as primary negative symptoms, quality of life, cognitive functioning, neuropsychological task performance, and occupational performance have a negligible correlation with psychosis (Strauss and Carpenter 1972; Hawk et al. 1975; Goldberg et al. 1993; Hagger et al. 1993; Strauss 1993; Buchanan et al. 1994) ; that the long-term course of schizophrenia is not robustly altered, despite the contemporaneous effectiveness of treating psychosis and reducing relapse rates with antipsychotic drugs; and that course and outcome are multidimensional phenomena in which any risk-benefit analysis of a treatment is complex.
Wyatt and I agree that medication-free periods are needed to address certain research questions and that it is desirable for the protocol-driven medication period to be brief and to involve appropriate patient selection and careful monitoring. I think such work is ethical and feasible, stressing the following points:
First, the length of time off medication during active psychosis in the earlier studies does not represent the brief periods usually employed in today's studies. Exit criteria for patients doing poorly during an off-medication protocol were not routine. Wyatt's analysis of the May et al. study (1981) has little relevance to the ethics of the medication-free research protocols of today.
Second, the random assignment, prospective, placebo and low-dose studies in which increased psychosis was not associated with worse subsequent course are more relevant (Mosher and Menn 1978; Matthews et al. 1979; Carpenter and Heinrichs 1983; Curson et al. 1986; Carpenter et al. 1987 Carpenter et al. , 1990 Kreisman et al. 1988; Jolley et al. 1990; Herz et al. 1991; Schooler 1991; Pietzcker et al. 1993; Schooler et al. 1993) . Social functioning, family satisfaction, negative symptoms, and side-effects advantages accrue, despite an increase in psychosis. These studies show that off-medication and placebo control studies can be conducted without adversely affecting the longerterm course of illness.
Even if there is only a short-term disadvantage in offmedication protocols, we still must justify the participation of patients. Here, I would emphasize (1) being off medication is a limited disadvantage that must be viewed in the overall context of treatment; (2) there may be tradeoff benefits, including enhanced monitoring, greater attention to differential diagnosis, implementation of effective psychosocial treatments, reduced adverse drug effects, and often the opportunity to participate in a treatment study in which the experimental approach is hypothesized to have certain advantages; (3) all treatment is not withheld in these circumstances. Rather, one element of treatment is controlled with protocol restrictions while other aspects of treatment may be enhanced. Close monitoring with early-out provisions that facilitate rapid neuroleptic intervention orchestrates a different approach to treatment, but one that is not fairly described as the withholding of treatment. Wyatt agrees, citing evidence that research-based treatment does have good clinical results (Cardon et al. 1976; Carroll et al. 1980; Kocsis et al. 1981; Macklin 1981; Kalman et al. 1982; McCrae 1982; Giller and Strauss 1984) . I would also emphasize that persons with schizophrenia have the right to volunteer their participation for altruistic reasons or self-interest. Data evaluating research risks do not support this right, depriving persons with schizophrenia this personal autonomy.
Specific guidelines to enhance the risk-benefit considerations associated with medication-free research are presented elsewhere (Carpenter et al., in press ). It is essential that discussion of the ethics of schizophrenia research be informed. There are necessary restraints on research, but we must also carefully protect our patients' vital interest in the acquisition of new knowledge. Hilts, P.J. Medical experts testify on tests done without consent. The New York Times, May 24, 1994b . "National" section. Huber, G.; Gross, G.; and Schiittler, R. Schizophrenic, Verlaufs-und soczialpsychiatrische Langzeituntersuchungen an den 1945 bis 1959 in Bonn hospitalisierten schizophrenen Kranken. Berlin, Germany: SpringerVerlag, 1979 
